Press Releases

EMERYVILLE, Calif., January 8, 2024 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO). Dr. Deutsch has been a part of the Nutcracker team since its inception, and previously served as its […]

EMERYVILLE, Calif., November 7, 2023 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented preclinical data for two of its therapeutic candidates: its latest therapeutic candidate, NTX-471, which targets CD47; and the company’s lead mRNA candidate targeting human papillomavirus (HPV)-driven tumors, NTX-250. These data […]

EMERYVILLE, Calif., November 1, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and […]

EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Cynthia Collins, to the company’s board of directors. Collins joins Nutcracker Therapeutics with more than four decades of experience working in the pharmaceutical and biotech industry. She currently is the […]

EMERYVILLE, Calif., May 2, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA. Nutcracker Therapeutics has developed its Nutshell™ platform of peptoid […]

EMERYVILLE, Calif., April 19, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April […]

EMERYVILLE, Calif., March 27, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present two posters outlining new preclinical data for its lead therapeutic candidate, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Fla., from April […]

EMERYVILLE, Calif., March 7, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO). Peters joins the company amidst an ongoing strengthening of the company’s therapeutic efforts, which included the appointment […]

EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors. Dr. Dietz brings to Nutcracker Therapeutics nearly three decades of experience in the investment banking and pharmaceutical industries. He is […]